Business Context and Reporting Period
Krystal Biotech, Inc. (KRYS) filed a Form 8-K on June 24, 2019. The filing serves as a Regulation FD disclosure regarding the announcement of positive results from the Phase 2 placebo-controlled clinical trial (GEM-2) for the investigational drug KB103.
Key Financial Metrics
This filing is a current report focused on clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the successful completion and positive outcome of the GEM-2 clinical trial for KB103. No financial changes versus prior periods are disclosed in this specific filing.
Guidance, Outlook, and Management Commentary
- Clinical Results: Management announced positive results from the Phase 2 GEM-2 study.
- Investor Communication: The Company held a webcasted conference call on June 24, 2019, at 8:45 a.m. EST to discuss the results. An audio archive was made available on the Company's website.
- Legal Disclaimer: The information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Key Facts for Investor Verification
- Verify the specific clinical endpoints and statistical significance of the "positive results" in the attached Press Release (Exhibit 99.1).
- Confirm the timeline for potential regulatory filings or Phase 3 trial initiation based on the GEM-2 data.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.